Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI) is expected to issue its results after the market closes on Tuesday, April 21st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Greenwich LifeSciences Stock Performance

Shares of Greenwich LifeSciences stock opened at $27.74 on Monday. The firm has a market capitalization of $384.20 million, a price-to-earnings ratio of -19.00 and a beta of 1.53. Greenwich LifeSciences has a 12-month low of $7.78 and a 12-month high of $34.10. The firm’s 50 day simple moving average is $25.67 and its two-hundred day simple moving average is $18.84.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp boosted its holdings in Greenwich LifeSciences by 19.3% during the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after buying an additional 15,831 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Greenwich LifeSciences by 1.4% during the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock worth $1,261,000 after buying an additional 1,972 shares in the last quarter. Man Group plc purchased a new stake in Greenwich LifeSciences during the fourth quarter worth $590,000. Marshall Wace LLP purchased a new stake in Greenwich LifeSciences during the second quarter worth $509,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Greenwich LifeSciences by 8.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 21,545 shares of the company’s stock worth $453,000 after buying an additional 1,700 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

Analyst Ratings Changes

GLSI has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. HC Wainwright increased their price objective on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 30th. Finally, Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $47.50.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.